|
|
| Line 1: |
Line 1: |
| | #REDIRECT [[Carvedilol#Adult Indications and Dosage]] |
|
| |
|
| __NOTOC__
| | [[Category:Beta Blockers]] |
| {{Carvedilol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==INDICATIONS AND USAGE==
| |
| | |
| ===Heart Failure===
| |
| | |
| COREG® is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to [[diuretics]], [[ACE inhibitors]], and [[digitalis]], to increase survival and, also, to reduce the risk of hospitalization [see [[Carvedilol drug interactions|Drug Interactions]] and [[Carvedilol clinical studies|Clinical Studies]]].
| |
| ===Left Ventricular Dysfunction Following Myocardial Infarction===
| |
| | |
| COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a [[myocardial infarction ]]and have a left ventricular [[ejection fraction ]]of ≤40% (with or without symptomatic [[heart failure]]) [see [[Carvedilol clinical studies|Clinical Studies]]].
| |
| ===Hypertension===
| |
| | |
| COREG is indicated for the management of [[essential hypertension]] [see [[Carvedilol clinical studies|Clinical Studies]]]. It can be used alone or in combination with other antihypertensive agents, especially[[ thiazide]]-type diuretics [see[[Carvedilol drug interactions|Drug Interactions]] ].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COREG (CARVEDILOL) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68#nlm34089-3 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |